AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
302.54B
Market cap302.54B
Price-Earnings ratio
29.12
Price-Earnings ratio29.12
Dividend yield
1.61%
Dividend yield1.61%
Average volume
2.08M
Average volume2.08M
High today
$196.41
High today$196.41
Low today
$187.01
Low today$187.01
Open price
$189.52
Open price$189.52
Volume
2.27M
Volume2.27M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$137.23
52 Week low$137.23

Stock Snapshot

The current AstraZeneca(AZN) stock price is $195.14, with a market capitalization of 302.54B. The stock trades at a price-to-earnings (P/E) ratio of 29.12 and offers a dividend yield of 1.61%.

As of 2026-07-05, AstraZeneca(AZN) stock has fluctuated between $187.01 and $196.41. The current price stands at $195.14, placing the stock +4.3% above today's low and -0.6% off the high.

The AstraZeneca(AZN)'s current trading volume is 2.27M, compared to an average daily volume of 2.08M.

During the past year, AstraZeneca(AZN) stock moved between $137.23 at its lowest and $212.71 at its peak.

During the past year, AstraZeneca(AZN) stock moved between $137.23 at its lowest and $212.71 at its peak.

AZN News

Benzinga 3d
Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance

The partnership follows regulatory clearance in China for a Phase 1/2 study evaluating Abbisko’s oral PD-L1 inhibitor, lumipodlin (ABSK043), alongside AstraZene...

Abbisko, AstraZeneca Team Up on Lung Cancer Drug Combo After China Trial Clearance
MarketWatch 3d
AstraZeneca advances Thursday, outperforms market - MarketWatch

...

AstraZeneca advances Thursday, outperforms market - MarketWatch
Seeking Alpha 3d
AstraZeneca inks kidney therapy deal worth up to $1.77B with China’s CSPC

AstraZeneca (AZN) has reached a partnership worth up to $1.77B with CSPC ‌Pharmaceutical Group (CSPCY) to develop and commercialize treatments for kidney diseas...

AstraZeneca inks kidney therapy deal worth up to $1.77B with China’s CSPC

Analyst ratings

83%

of 29 ratings
Buy
82.8%
Hold
10.3%
Sell
6.9%

More AZN News

TipRanks 3d
AstraZeneca, Abbisko Therapeutics enter strategic collaboration

Abbisko Therapeutics announced that it has entered into a strategic collaboration agreement with AstraZeneca (AZN) to jointly advance the clinical development o...

TipRanks 3d
Abbisko and AstraZeneca Launch Joint Trial of Novel NSCLC Combination

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

TipRanks 4d
AstraZeneca’s VECTRA-01 Trial Targets Next-Generation Gains in Advanced Prostate Cancer

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium fo...

TipRanks 4d
AstraZeneca’s Surovatamig Trial Targets Antibody-Driven Kidney Disease

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium fo...

TipRanks 4d
AstraZeneca Adds 14,784 Shares Under Employee Schemes on LSE Main Market

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Nasdaq 4d
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)

AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the European Commission (EC) has approved their blockbuster antibody-drug conjugate (A...

AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)
TipRanks 5d
AstraZeneca’s ASCERTAIN Trial Wrap-Up: What Prostate Cancer Data Could Mean for AZN Investors

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for mor...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.